ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
GAUDIUM IVF AND WOMEN HEALTH LIMITED intimated a board meeting on 12 Nov 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. No financial figures are disclosed in this intimation.
Gaudium IVF and Women Health Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulations.
Gaudium IVF conducted its 11th Annual General Meeting on September 28, 2026, via video conferencing, transacting all businesses specified in the AGM notice.
Gaudium IVF and Women Health Limited commenced operations at its new IVF Centre/Hub in Gurgaon, Haryana, effective September 24, 2026.
Gaudium IVF and Women Health Limited has intimated the exchange about sending physical letters to shareholders for accessing the Annual Report for FY 2025-26.
Gaudium IVF and Women Health Limited submitted its Annual Report for the Financial Year 2025-26. The 11th Annual General Meeting is scheduled for September 28, 2026.
Gaudium IVF and Women Health Limited will hold its 11th AGM on September 28, 2026. The meeting will be conducted via Video Conferencing to consider several resolutions.
Gaudium IVF reported Q1 FY27 consolidated revenue of Rs. 1,937.66 Lakhs, up 9.13% YoY, while front-loading expansion costs for new hubs and AI integration.
Gaudium IVF and Women Health Limited has re-appointed Ram Rattan & Associates as Internal Auditor for a 12-month term.
Gaudium IVF and Women Health Limited has re-appointed Ram Rattan & Associates as the Internal Auditor for a 12-month term.
Gaudium IVF's Q1FY27 revenue grew 9.13% YoY to ₹19.4 Crore. The company also announced the commencement of its new South Extension IVF hub.
Gaudium IVF And Women Health Ltd reported revenue from operations of ₹19.4 Cr (+9.0% YoY) and net profit of ₹1.8 Cr (-41.9% YoY) for Q1 FY27.
Gaudium IVF and Women Health Ltd will hold a board meeting on August 13, 2026, to approve its quarterly financial results.
Gaudium IVF launched a new AI-powered centre in South Delhi. This marks the first milestone in its planned 19-centre nationwide expansion strategy.
Gaudium IVF will commence commercial operations at its new South Extension centre on July 16, 2026. This expansion aligns with the company's IPO prospectus objectives.
Gaudium IVF issued a corrigendum to correct typographical errors in consolidated results. The changes relate only to comparative figures for March 31, 2025.
Gaudium IVF approved a new Gaudium Women Hospital in Lucknow costing ₹15 crore. A 30‑year lease will let the company develop, operate and manage it.
Gaudium IVF reported strong FY26 performance with consolidated revenue at ₹10,435.70 Lakhs and PAT of ₹2,448.85 Lakhs, driven by its recent IPO and AI-led clinical excellence.
Gaudium IVF reported FY26 revenue of ₹104.35 Crore, representing 48% year-on-year growth. The company achieved a record 40% EBITDA margin in Q4FY26.
Gaudium IVF And Women Health Ltd reported revenue from operations of ₹30.4 Cr (+13.0% YoY) and net profit of ₹8.4 Cr (+29.2% YoY) for Q4 FY26.
Gaudium IVF reported consolidated annual profit of ₹24.49 Crore on revenue of ₹104.36 Crore. The Board approved these audited results for the period ending March 2026.
NCLT New Delhi Bench rejected an insolvency petition filed against Gaudium IVF by Ramaa Capital. This decision removes immediate legal risk from the operational creditor's IBC claim.
Gaudium IVF scheduled a board meeting for May 28, 2026, to approve annual audited financial results. The trading window remains closed until 48 hours after declaration.
Gaudium IVF and Women Health Ltd clarified to BSE and NSE that there is no undisclosed price-sensitive information impacting its share price movement. The company confirmed all material events have been disclosed as per SEBI regulations, stating recent price fluctuations are purely market-driven. Operations and performance remain as previously reported to the exchanges.
Gaudium IVF and Women Health Limited announced a change in its Corporate Identification Number (CIN) to L85100DL2015PLC278296. This update follows the company's listing on the NSE and BSE, transitioning its status from 'Unlisted' to 'Listed'.
Gaudium IVF and Women Health Limited updated the Exchange regarding a dispute with Neomile Corporate Advisory Limited. The Bombay High Court disposed of the arbitration petition and appointed Hon’ble Mr. Justice Nitin Jamdar as the Sole Arbitrator. The company and its promoter, Dr. Manika Khanna, are parties to the proceedings, which currently have no financial impact.
Gaudium IVF and Women Health Limited announced that the Bombay High Court has disposed of a Commercial Arbitration Petition filed by Neomile Corporate Advisory Limited. Mr. Justice Nitin Jamdar has been appointed as the Sole Arbitrator. The dispute relates to alleged IPO advisory services and has no immediate financial implication.
Gaudium IVF and Women Health Ltd informed that the Bombay High Court has disposed of an arbitration petition filed by Neomile Corporate Advisory regarding IPO services. Former Chief Justice Nitin Jamdar has been appointed as the Sole Arbitrator. The company stated there is currently no financial implication from these proceedings.